EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Parva Bhatt, Colin Kloock, Raymond Comenzo

Current Oncology · 15.02.2023 · 30 (2) · 2322-2347

DOI: 10.3390/curroncol30020179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 15.02.2023. Verfasst von Parva Bhatt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tufts University Medical Center, Boston, MA 02145, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma remains an incurable disease with the usual disease course requiring induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance. Risk stratification tools and cytogenetic alterations help inform individualized therapeutic choices for patients in hopes of achieving long-term remissions with preserved quality of life. Unfortunately, relapses occur at different stages of the course of the disease owing to the biological heterogeneity of the disease. Addressing relapse can be complex and challenging as there are both therapy- and patient-related factors to consider. In this broad scoping review of available therapies in relapsed/refractory multiple myeloma (RRMM), we cover the pharmacologic mechanisms underlying active therapies such as immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (mAbs), traditional chemotherapy, and Venetoclax. We then review the clinical data supporting the use of these therapies, organized based on drug resistance/refractoriness, and the role of autologous stem cell transplant (ASCT). Approaches to special situations during relapse such as renal impairment and extramedullary disease are also covered. Lastly, we look towards the future by briefly reviewing the clinical data supporting the use of chimeric antigen receptor (CAR-T) therapy, bispecific T cell engagers (BITE), and Cereblon E3 Ligase Modulators (CELMoDs).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationHumansQuality of LifeTransplantation, AutologousNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Venetoclaxautologous stem cell transplantchemotherapyextramedullary diseaseimmunomodulatory agentsmonoclonal antibodiesmultiple myelomaproteasome inhibitorsrelapsed/refractoryrenal impairment

Autor:innen und Institutionen

  • Tufts University Medical Center, Boston, MA 02145, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Bhatt, P., Kloock, C., & Comenzo, R. (2023). Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Current Oncology, 30(2), 2322-2347. https://doi.org/10.3390/curroncol30020179

Vancouver

Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Current Oncology. 2023;30(2):2322-2347. doi:10.3390/curroncol30020179

BibTeX
@article{Bhatt2023,
  author = {Bhatt, Parva and Kloock, Colin and Comenzo, Raymond},
  title = {Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {2},
  pages = {2322--2347},
  doi = {10.3390/curroncol30020179}
}
Kostenlos starten →